Patients with non-small-cell lung cancer (NSCLC) whose tumours harbour activating
mutations within the epidermal growth factor receptor (EGFR) frequently derive significant …

Lung neoplasms are the leading cause of death by cancer worldwide. Non-small cell lung
cancer (NSCLC) constitutes more than 80% of all lung malignancies and the majority of …

Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in
melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer …

Introduction Brain metastases (BM) are common in non-small-cell lung cancer (NSCLC).
However, the baseline incidence and evolution of BM over time in oncogene-driven …

Background ALK fusion genes occur in a subset of non-small-cell lung cancers (NSCLCs).
We assessed the tolerability and activity of crizotinib in patients with NSCLC who were …

Purpose The ROS1 tyrosine kinase is activated through ROS1 gene rearrangements in 1%
to 2% of non–small-cell lung cancers (NSCLCs), which confer sensitivity to treatment with …

Introduction Molecular genetic analyses of lung adenocarcinoma have recently become
standard of care for treatment selection. The Lung Cancer Mutation Consortium was formed …

PURPOSE To provide evidence-based recommendations to practicing clinicians on
radiographic imaging and biomarker surveillance strategies after definitive curative-intent …

Purpose Intracranial efficacy of first-line crizotinib versus chemotherapy was compared
prospectively in the phase III PROFILE 1014 study in ALK-positive non–small-cell lung …

Background: This study aimed to explore the potential association of mutation in the
epidermal growth factor receptor (EGFR) with brain metastases in patients with pulmonary …